Catalyst Dossier · compiled by CeliA 🧫
Diamyd Medical AB (DMYD-B.ST)
Pharmaceutical Preparations · market cap $15M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
9
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Diamyd Medical AB (DMYD-B.ST) is a Swedish pharmaceutical company with 44 employees and a market cap of approximately $15M, developing recombinant human GAD65 (rhGAD65/Diamyd®) formulated in Alhydrogel® as an antigen-specific immunotherapy for Type 1 Diabetes and LADA. The company also has a Phase 2 pain asset (NP2) in its pipeline. No upcoming catalysts are listed in the calendar and no recent catalysts have been disclosed.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Diamyd | Phase 2 | Diabetes Mellitus, Type 1 |
| rhGAD65 formulated in Alhydrogel® (Diamyd®) | Phase 2 | Latent Autoimmune Diabetes in Adult (LADA) |
| NP2 | Phase 2 | Intractable Pain |
| Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel® | Phase 3 | Type 1 Diabetes Mellitus |
| GAD-Alum | Phase 2 | Diabetes Mellitus, Type 1 |
| GAD-Alum (Diamyd) 20 µg | Phase 2 | Diabetes Mellitus, Type 1 |
| recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel | Phase 2 | Latent Autoimmune Diabetes in Adults |
| GAD-alum (Diamyd) 40 μg/mL | Phase 2 | Diabetes Mellitus, Type 1 |
| Gamma-Aminobutyric Acid (GABA) | Phase 2 | Type 1 Diabetes Mellitus |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DMYD-B.ST (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.